Clinical Trials Browser

Interventional × sotorasib × 90 days × Clear all

NCT05920356 2026-06-04

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Phase 2 Recruiting

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT06333951 2026-05-28

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06807619 2026-05-22

A Study of Sotorasib in People With Brain Tumors

Phase 1 Recruiting

Brain Neoplasms

NCT07172919 2026-05-14

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation

Phase 2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT05638295 2026-05-13

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT07012031 2026-05-13

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04380753 2026-05-06

AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).

Phase 1 Completed

12 enrolled 12 charts

Other solid neoplasm

Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation

NCT05118854 2026-05-04

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Phase 2 Recruiting

Lung Neoplasms

NCT07563738 2026-05-04

TEADCO

Phase 1/2 Recruiting

GastrointestinalOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms

NCT04303780 2026-04-30

Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

Phase 3 Active not recruiting

345 enrolled 11 charts

KRAS p, G12c Mutated /Advanced Metastatic NSCLC

NCT05398094 2026-04-30

MERIT-lung

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05198934 2026-04-27

CodeBreak300

Phase 3 Completed

160 enrolled 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT06252649 2026-04-24

CodeBreaK 301

Phase 3 Recruiting

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT05036291 2026-04-22

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumor

NCT07543172 2026-04-21

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

Phase 2 Not yet recruiting

Lung Neoplasms

NCT06497556 2026-04-20

Krascendo 1

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04892017 2026-04-08

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06249282 2026-04-03

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06582771 2026-03-25

A Study of Sotorasib in People With Non-Small Cell Lung Cancer

Phase 2 Recruiting

Non Small Lung Cancer

NCT06804824 2026-03-18

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Phase 1/2 Active not recruiting

713 enrolled 1 FDA

Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors